Bladder Cancer Screening at the DuPont Chambers Works: A New Initiative

Publisher Website
Google Scholar
Abstract
Persona ocoupationally exposed to known or suspected human bladder carcinogens are being recruited for a 3-year casecontrol study of the efficacy of and adherence to a home selftesting protocol for microscopic hematuria as a method for early detection of treatable urologio conditions, including bladder cancer. All employees of the DuPont Chambers Works who are currently in the tumor surveillance program (those known to have been exposed to ß-naphtbylamine, benzidine, and 4,4' - methylenebis(2-ohloroaniline)) will be asked to participate. Age-matched controls will be recruited from the community. Recent advances in identifying clinical signs of underlying bladder disease among the asymptomatic have been implemented in our screening design. Quarterly urinalyses will include the traditional microscopic examination of the urine to detect red blood cells. Participants will test their urine for miorohematuria using the Ames HemastixR for 14 consecutive days every other quarter. On alternating quarters, cytologies will be performed. Persons who test positive (hematuria and/ or abnormal cytology) will be referred for a complete urologic workup.

This publication has 0 references indexed in Scilit: